Lilly Discusses GLP-1 Strategy At ADA, Readies For Dulaglutide Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to present dulaglutide as another option for patients and expand the market instead of trying to switch patients already using GLP-1s, but analysts are interested in how it stacks up against the competition.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.